Contents

Search

Lutrepulse (Relisorm, Factrel, GnRH, GnRH1)

Tradenames: Lutrepulse, Relisorm, Factrel. Indications: 1) evaluation of response to gonadotropins 2) evaluation of abonormal gonadotropin regulation as in precocious puberty & delayed puberty 3) ovulation Dosage: - women & girls > 12 years of age: - 100 ug SC during early follicular phase of menstrual cycle (days 1-7) Injection: 0.1 mg & 0.5 mg (2 mL) Adverse effects: 1) not common (1-10%) - pain at site of injection 2) uncommon (< 1%) - flushing, lightheadedness, headache, rash, nausea, abdominal discomfort Mechanism of action: 1) GnRH (GnRH1) 2) stimulates LH & FSH secretion from the anterior pituitary 3) pulsatile secretion* is essential for activity of GnRH 4) increased frequency of GnRH pulses occurs during the early follicular phase of the menstrual cycle * Continuous stimulation with long-acting GnRH agonists (goserelin, gonadorelin) effectively castrates men with prostate cancer.

Interactions

drug adverse effects of GnRH agonists

Related

gonadotropin-releasing hormone [GNRH] receptor gonadotropin-releasing hormone/factor 1; gonadoliberin 1; LH/FSH-releasing hormone 1; gonadorelin (GnRH1, LHRH-1)

General

gonadotropin-releasing hormone agonist (GnRH analog)

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  2. Uniprot :accession P01148
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998